Cargando…
Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo
Estrogen receptor negative (ER(−)) breast cancer is aggressive, responds poorly to current treatments and has a poor prognosis. The NF-κB signaling pathway is implicated in ER(−) tumorigenesis. Aspirin (ASA) is chemopreventive against ER(+) but not for ER(−) breast cancers. Nitric oxide-releasing as...
Autores principales: | Nath, Niharika, Chattopadhyay, Mitali, Rodes, Deborah B., Nazarenko, Anna, Kodela, Ravinder, Kashfi, Khosrow |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331965/ https://www.ncbi.nlm.nih.gov/pubmed/26184135 http://dx.doi.org/10.3390/molecules200712481 |
Ejemplares similares
-
Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signaling
por: Kodela, Ravinder, et al.
Publicado: (2015) -
NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties
por: Kashfi, Khosrow, et al.
Publicado: (2015) -
Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling()
por: Vannini, Federica, et al.
Publicado: (2015) -
Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH‐naproxen (AVT‐219) a dual NO‐ and H(2)S‐releasing hybrid
por: Chattopadhyay, Mitali, et al.
Publicado: (2016) -
NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain
por: Fonseca, Miriam D, et al.
Publicado: (2015)